Adjuvant pembrolizumab confers durable RFS benefit in resected stage III melanoma

Source: Healio, May 2020

Adjuvant pembrolizumab taken for up to 1 year conferred a durable, clinically meaningful RFS benefit for patients with resected high-risk stage III melanoma, according to study results presented during the ASCO20 Virtual Scientific Program.

The RFS improvement — observed at 3-year median follow-up of the randomized, phase 3 EORTC 1325/KEYNOTE-054 trial — remained consistent across subgroups, researchers noted.

“In the old era, for about 50 years, we tried to define the role of adjuvant therapy for stage III melanoma,” Alexander M.M. Eggermont, MD, PhD, FASCO, professor of oncology at Paris-Sud University and professor of oncological surgery and chair of the International Research Network on Cancer at Erasmus University of Rotterdam in the Netherlands, said during a presentation. “The last 5 years, we have been dedicated to evaluating drugs that are active in this setting.”

READ THE ORIGINAL FULL ARTICLE